Fallopian Tube Neoplasms
📧 Sign up to get email alerts when something new happens for Fallopian Tube Neoplasms.
Sign up freeTop drugs studied for this disease
-
EMA approval · 2026-07-07EMA Authorised: Abevmy (bevacizumab) — Biosimilar Collaborations Ireland Limited
EMA authorises a biosimilar version of bevacizumab (Abevmy) for multiple cancer indications, expanding access to this biologic therapy.
-
EMA approval · 2026-06-10EMA Authorised: Zejula (niraparib (tosilate monohydrate)) — GlaxoSmithKline Trading Services Limited
The EMA authorised Zejula (niraparib tosilate monohydrate) for ovarian, fallopian tube, and peritoneal neoplasms, under GlaxoSmithKline Trad…
-
CLINICAL_TRIALS trial_result · 2026-03-09Clinical Trial Update: Pembrolizumab/Placebo Plus Paclitaxel With or Without Bevacizumab for Platinum-resistant Recurrent Ovarian Cancer (MK-3475-B96/KEYNOTE-B96/ENGOT-ov65). [Phase 3]
Phase 3 trial assessing pembrolizumab with paclitaxel, with or without bevacizumab, for platinum-resistant recurrent ovarian cancer; results…
-
CLINICAL_TRIALS research · 2026-01-12Clinical Trial Update: OV Precision: Study Examining the Benefit of a Tumor- and Patient-specific Cancer Therapy [NA]
Clinical trial update for the OV Precision study evaluating tumor- and patient-specific cancer therapy in ovarian and fallopian tube neoplas…
-
EMA approval · 2025-11-26EMA Authorised: Zejula (niraparib (tosilate monohydrate)) — GlaxoSmithKline Trading Services Limited
The EMA authorised Zejula for fallopian tube neoplasms, peritoneal neoplasms, and ovarian neoplasms. GlaxoSmithKline Trading Services Limite…
- Want full summaries, importance scores, and drug timelines? Upgrade to Plus or Pro.
-
CLINICAL_TRIALS trial_result · 2021-01-20Clinical Trial Update: Compare Fallopian Tube Cells Collected by Cytuity With Removed Ovarian/Tubal Tissue to Determine Presence of Malignancy
Clinical trial evaluating whether fallopian tube cells collected by Cytuity can determine the presence of malignancy compared with removed o…
-
CLINICAL_TRIALS trial_result · 2020-11-10Clinical Trial Update: Efficacy and Safety of Niraparib Combined With Bevacizumab in Platinum Refractory/Resistant Recurrent Ovarian Cancer [Phase 2]
Phase 2 trial evaluating niraparib in combination with bevacizumab for platinum-refractory/resistant recurrent ovarian cancer; efficacy and …
-
CLINICAL_TRIALS trial_result · 2020-10-19Clinical Trial Update: Comparing Two Treatments for Ovarian Cancer: Standard Chemotherapy Plus Enzastaurin, or Placebo ("Sugar Pill") [Phase 2]
Phase 2 trial comparing standard chemotherapy plus enzastaurin versus placebo in ovarian cancer; completed with results posted.
-
EMA withdrawal · 2017-11-10EMA Application withdrawn: Kyomarc (bevacizumab) — Amgen Europe B.V.
The EMA withdrew the application for Kyomarc (bevacizumab) from Amgen Europe B.V., relating to several carcinomas and neoplasms.
-
CLINICAL_TRIALS trial_result · 2006-10-02Clinical Trial Update: Use of ACA 125 in Patients With Ovarian Cancer: Safety and Immune Response [Phase 1, Phase 2]
Phase 1/2 clinical trial evaluating ACA 125 in patients with ovarian cancer, focusing on safety and immune response.